Trinaxid 40 Mg/2 Ml, 100 Mg/5 Ml, 300 Mg/15 Ml 40 mg/2 mL, 100 mg/5 mL, 300 mg/15 mL Concentrate for solution for infusion
PDF Leaflet Revision Date: 18 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced colorectal cancer.
Dosage (summary)
350 mg/mu00b2 IV every 3 weeks for monotherapy; 80 mg/mu00b2 weekly or 180 mg/mu00b2 every 2 weeks for combination therapy.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment.
Key Drug Interactions
- Azole antifungals
- St. John's Wort
- Live vaccines
Contraindications
- Severe hypersensitivity to irinotecan
- Chronic inflammatory bowel disease
- Bilirubin > 1.5 times ULN
Common side effects
- Delayed diarrhoea
- Neutropenia
- Nausea
- Vomiting
- Alopecia
Counselling Points
- Stay hydrated
- Report diarrhoea immediately
- Use effective contraception during treatment
Serious warnings
- Risk of severe diarrhoea
- Monitor for febrile neutropenia
- Use in specialized units only
Important Disclaimer
The Trinaxid 40 Mg/2 Ml, 100 Mg/5 Ml, 300 Mg/15 Ml 40 mg/2 mL, 100 mg/5 mL, 300 mg/15 mL Concentrate for solution for infusion professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
